Jian-Yu Lian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jian-Yu Lian has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Peng-Ting Chen
Biomedical Engineering Department, National Cheng Kung University, Tainan, Taiwan
2 shared publications - An-Shun Liu
National Center for Instrumentation Research, National Institutes of Applied Research, No. 20, R&D Road VI, Hsinchu Science Park, Hsinchu City 300092, Taiwan
1 shared publication - C. Benson Kuo
Department of Regulatory and Quality Sciences, University of Southern California, Los Angeles, CA, 90033, United States
1 shared publication - Matthew Sing
Department of Biomedical Engineering, National Cheng Kung University, No.138, Shengli Rd, North District, Tainan, 701, Taiwan, 886 2757575 ext 63438
1 shared publication - Mu-Hsun Tseng
Department of Biomedical Engineering, The International Institute of Medical Device Innovation, National Cheng Kung University (NCKU), No. 1, University Road, Tainan City 701, Taiwan
1 shared publication - Wei-Bin Chen
Department of Biomedical Engineering, National Cheng Kung University, No.138, Shengli Rd, North District, Tainan, 701, Taiwan, 886 2757575 ext 63438
1 shared publication
Latest Publications
- Open Access
- 24 July 2025
- Published by MDPI AG in Sustainability
- Vol. 17 (15) , 6740
An Interpretive Structural Modeling Approach for Biomedical Innovation Strategy Models with Sustainability
In recent years, the biomedical startup industry has flourished, and yet, it still faces challenges in adapting to changing market demands. Meanwhile, the widespread use of single-use medical devices generates significant waste, posing threats to environmental sustainability. Addressing this issue has become a critical challenge for humanity today. The study aimed to delve into the specific difficulties faced by Taiwanese biomedical entrepreneurs during the innovation and development of medical devices from a sustainability perspective and to explore solutions. This study collected first-hand experiences and insights from Taiwanese biomedical entrepreneurs through a literature review and expert questionnaires. It employed Interpretive Structural Modeling to analyze the development stages and interrelationships of biomedical device startups for building sustainable biomedical innovation. The Clinical Needs Assessment is revealed as the most influential factor, shaping Regulatory Feasibility Evaluation, Clinical Trial Execution, and Market Access Compliance. Our findings provide a structured problem-solving framework to assist biomedical startups in overcoming challenges while incorporating energy-saving and carbon reduction processes to achieve environment sustainability goals. The results of this study show that biomedical innovation practitioners should prioritize integrating sustainability considerations directly into the earliest stage of a Clinical Needs Assessment.
- 24 July 2025
- Published by MDPI AG in Sustainability
- Vol. 17 (15) , 6740
Open AccessAn Interpretive Structural Modeling Approach for Biomedical Innovation Strategy Models with Sustainability
In recent years, the biomedical startup industry has flourished, and yet, it still faces challenges in adapting to changing market demands. Meanwhile, the widespread use of single-use medical devices generates significant waste, posing threats to environmental sustainability. Addressing this issue has become a critical challenge for humanity today. The study aimed to delve into the specific difficulties faced by Taiwanese biomedical entrepreneurs during the innovation and development of medical devices from a sustainability perspective and to explore solutions. This study collected first-hand experiences and insights from Taiwanese biomedical entrepreneurs through a literature review and expert questionnaires. It employed Interpretive Structural Modeling to analyze the development stages and interrelationships of biomedical device startups for building sustainable biomedical innovation. The Clinical Needs Assessment is revealed as the most influential factor, shaping Regulatory Feasibility Evaluation, Clinical Trial Execution, and Market Access Compliance. Our findings provide a structured problem-solving framework to assist biomedical startups in overcoming challenges while incorporating energy-saving and carbon reduction processes to achieve environment sustainability goals. The results of this study show that biomedical innovation practitioners should prioritize integrating sustainability considerations directly into the earliest stage of a Clinical Needs Assessment.
- Open Access
- 11 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e67552
Regulatory Insights From 27 Years of Artificial Intelligence/Machine Learning–Enabled Medical Device Recalls in the United States: Implications for Future Governance
Background: Artificial intelligence/machine learning (AI/ML) has revolutionized the health care industry, particularly in the development and use of medical devices. The US Food and Drug Administration (FDA) has authorized over 878 AI/ML–enabled medical devices, reflecting a growing trend in both quantity and application scope. Understanding the distinct challenges these devices present in terms of FDA regulation violations is crucial for effectively avoiding recalls. This is particularly pertinent for proactive measures regarding medical devices. Objective: This study explores the impact of AI/ML on medical device recalls, focusing on the distinct causes associated with AI/ML–enabled devices compared with other device types. Recall information associated with 510(k)-cleared devices was obtained from openFDA. Three recall cohorts were established: “All 510(k) devices recall,” “software-related devices recall,” and “AI/ML devices recall.” Methods: Recall information for 510(k)-cleared devices was obtained from openFDA. AI/ML-enabled medical devices were identified based on FDA listings. Three cohorts were established: “All 510(k) devices recall,” “software-related devices recall,” and “AI/ML devices recall.” Root cause analysis was conducted for each recall event. Results: The results indicate that while the top 5 recall root causes are relatively similar across the 3 control groups, the proportions vary, with AI/ML devices showing a higher impact for 87% of all recalls. Design and development–related factors play a significant role in recalls of AI/ML devices with root causes related to device design and software design accounting for 50% of recalls, emphasizing the importance of thorough planning, user feedback incorporation, and validation during the development process to reduce the probability of recalls. In addition, changes in software, including design changes and control changes, also contribute substantially to recalls in AI/ML devices. Conclusions: In conclusion, this study provides valuable insights into the unique challenges and considerations associated with –enabled medical device recalls, offering guidance for manufacturers to enhance verification plans and mitigate risks in this rapidly evolving technological landscape.
- 11 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e67552
Open AccessRegulatory Insights From 27 Years of Artificial Intelligence/Machine Learning–Enabled Medical Device Recalls in the United States: Implications for Future Governance
Background: Artificial intelligence/machine learning (AI/ML) has revolutionized the health care industry, particularly in the development and use of medical devices. The US Food and Drug Administration (FDA) has authorized over 878 AI/ML–enabled medical devices, reflecting a growing trend in both quantity and application scope. Understanding the distinct challenges these devices present in terms of FDA regulation violations is crucial for effectively avoiding recalls. This is particularly pertinent for proactive measures regarding medical devices. Objective: This study explores the impact of AI/ML on medical device recalls, focusing on the distinct causes associated with AI/ML–enabled devices compared with other device types. Recall information associated with 510(k)-cleared devices was obtained from openFDA. Three recall cohorts were established: “All 510(k) devices recall,” “software-related devices recall,” and “AI/ML devices recall.” Methods: Recall information for 510(k)-cleared devices was obtained from openFDA. AI/ML-enabled medical devices were identified based on FDA listings. Three cohorts were established: “All 510(k) devices recall,” “software-related devices recall,” and “AI/ML devices recall.” Root cause analysis was conducted for each recall event. Results: The results indicate that while the top 5 recall root causes are relatively similar across the 3 control groups, the proportions vary, with AI/ML devices showing a higher impact for 87% of all recalls. Design and development–related factors play a significant role in recalls of AI/ML devices with root causes related to device design and software design accounting for 50% of recalls, emphasizing the importance of thorough planning, user feedback incorporation, and validation during the development process to reduce the probability of recalls. In addition, changes in software, including design changes and control changes, also contribute substantially to recalls in AI/ML devices. Conclusions: In conclusion, this study provides valuable insights into the unique challenges and considerations associated with –enabled medical device recalls, offering guidance for manufacturers to enhance verification plans and mitigate risks in this rapidly evolving technological landscape.